Mark Socinski, MD


Executive Medical Director, Florida Hospital Cancer Institute
Specializes in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma
Mark Socinski, MD

Dr. Mark A. Socinski is the Executive Medical Director of the Florida Hospital Cancer Institute. Dr. Socinski is a board-certified, fellowship-trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small-cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer.

Dr. Socinski received his medical degree from the University of Vermont in Burlington, VT. He completed his medical residency in internal medicine at Beth Israel Hospital/Harvard Medical School and completed training in medical oncology at the Dana-Farber Cancer Institute/Harvard Medical School. Dr. Socinski holds memberships in numerous professional societies such as the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He serves as co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials.


  • Mesothelioma
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Thoracic Oncology

Awards and Honors

  • PNC/UPCI Director’s Distinguished Scholar Award
  • Best Cancer Doctors, Good Housekeeping Magazine
  • America’s Top Doctors, Castle Connolly Medical Ltd
  • Hiram E. Buttles Award for Excellence in Pathology
  • Woodbury Alumni/Century Club Award for Outstanding Clinical Proficiency in Medicine
  • Herbert Martin Sr. Award for Outstanding Clinical Proficiency in Neurology
  • Teacher of the Year University of Vermont, School of Medicine Medical House Staff, MCHV
  • Teacher of the Year University of Vermont, School of Medicine Medical House Staff, MCHV


  1. Clinicopathologic features of advanced squamous non-small cell lung cancer.
    Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N.
    J Thorac Oncol. 2016 Jun 10. pii: S1556-0864(16)30499-3. doi: 10.1016/j.jtho.2016.05.024. [Epub ahead of print] Review.
    PMID: 27296106 [PubMed - as supplied by publisher]
  2. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1 directed therapy.
    Villaruz LC, Socinski MA.
    Clin Pharmacol Ther. 2016 Apr 18. doi: 10.1002/cpt.385. [Epub ahead of print] No abstract available.
    PMID: 27090296 [PubMed - as supplied by publisher]
  3. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators.
    Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.
    PMID: 26045340 [PubMed - indexed for MEDLINE]
  4. Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.
    Villaruz LC, Socinski MA.
    Eur J Cancer. 2016 Mar;56:162-71. doi: 10.1016/j.ejca.2015.12.022. Epub 2016 Feb 12. Review.
    PMID: 26875112 [PubMed - in process] Free PMC Article
  5. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
    Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR.
    Ann Oncol. 2016 May 20. pii: mdw214. [Epub ahead of print]
    PMID: 27207107 [PubMed - as supplied by publisher]

Points of Difference

  • Highly Experienced Thoracic Robotic Surgeon
  • Award-Winning Innovations
  • Multidisciplinary Approach
  • Clinical Trials
  • Minimally Invasive Procedures
  • Preoperative Patient Education
  • National Accreditations and Certifications
  • Nationally Ranked Cancer Program